International Assets Investment Management LLC Acquires 4,659 Shares of Eli Lilly and Company $LLY

Key Points

• International Assets Investment Management LLC increased its Eli Lilly stake by 27% in the fourth quarter, buying 4,659 more shares and bringing its total holding to 21,937 shares worth about $23.6 million.
• Wall Street sentiment remains upbeat, with multiple analysts reiterating buy/outperform views and the consensus rating sitting at Moderate Buy; the average target price is $1,218.33.
• Eli Lilly continues to post strong fundamentals, reporting $8.55 EPS and $19.8 billion in quarterly revenue, both above estimates, while investors also watch growth drivers like GLP-1 drug demand, weight-loss pill prospects, and a new $4.5 billion manufacturing investment in Indiana.

International Assets Investment Management LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,937 shares of the company's stock after acquiring an additional 4,659 shares during the period. Eli Lilly and Company makes up approximately 1.3% of International Assets Investment Management LLC's investment portfolio, making the stock its 12th largest holding. International Assets Investment Management LLC's holdings in Eli Lilly and Company were worth $23,575,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $25,000. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $33,000. Dorato Capital Management bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $36,000. New England Capital Financial Advisors LLC increased its position in shares of Eli Lilly and Company by 142.9% during the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock worth $37,000 after acquiring an additional 20 shares in the last quarter. Finally, Vermillion & White Wealth Management Group LLC increased its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after acquiring an additional 16 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on LLY shares. Sanford C. Bernstein reissued an "outperform" rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Barclays increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Monday, May 4th. Morgan Stanley restated an "overweight" rating and set a $1,344.00 target price on shares of Eli Lilly and Company in a report on Friday, May 1st. Scotiabank restated an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Guggenheim restated a "buy" rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,218.33.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

Eli Lilly and Company Price Performance

NYSE:LLY opened at $948.01 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a market cap of $892.78 billion, a P/E ratio of 33.68, a P/E/G ratio of 1.04 and a beta of 0.48. The firm's fifty day moving average price is $943.90 and its two-hundred day moving average price is $990.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the company earned $3.34 earnings per share. The company's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.